NCT Number: NCT02375841
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
The purpose of this study is to learn more about the way physicians communicate with brain tumor patients. This study will look at how oncologists provide information about brain tumors, brain scan results, and treatment options. This study will look at how oncologists provide information about brain tumors, brain scan results, and treatment options. Ultimately, the investigators hope to use these findings to improve communication between patients, caregivers and their doctors.
This study is active but is not currently recruiting participants.
Key information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Henry Ford Hospital, Detroit, Michigan, United States
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patient Inclusion Criteria:
- 18 years or older
- Pathologic diagnosis of WHO grade IV glioma, as per MSKCC medical record or outside medical record.
- In the judgment of the consenting professional, proficiency in English that will allow the participant to be able to complete study questionnaires and assessments. Many of the study assessments are available only in English.
- At the time of consent, orientation to self, place, month and year
Caregiver Inclusion Criteria:
- 18 years or older
- Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her informal (unpaid) care (i.e., physical or emotional assistance).
- In the judgment of the consenting professional, proficiency in English that will allow to complete study questionnaires and assessments. Many of the study assessments are available only in English.
Oncologist Inclusion Criteria:
- Treating Neuro-Oncologist in the Department of Neurology
Exclusion criteria
Patient Exclusion Criteria:
- A patient will be excluded if in the opinion of his/her attending neuro-oncologist or the covering neuro-oncologist, he does not have the capacity to consent to the study based on clinical evaluation
- Aphasia precluding comprehension and verbalization of consent to participate, in the estimation of the attending physician.
Caregiver Exclusion Criteria:
- There are no caregiver exclusion criteria.
Treatment and study plan
Primary outcomes
-
number of responses from patients, to 3 yes/no questions
Time frame: 2 years
The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)
-
number of responses from caregivers to 3 yes/no questions
Time frame: 2 years
The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)
-
number of responses from physicians to 3 yes/no questions
Time frame: 2 years
The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)
Sponsors and collaborators
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Collaborators
- Weill Medical College of Cornell University
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- Mar 3, 2015
- Registry last updated
- Mar 18, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318
Anaplastic Oligodendroglioma of Brain (Diagnosis), Astrocytoma
Baltimore, Maryland, United States
View Trial DetailsA Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
Astrocytoma, Brain Cancer
San Francisco, California, United States
View Trial DetailsRuxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
NCT06991101
Astrocytoma, Brain Cancer
Miami, Florida, United States
View Trial DetailsPilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
NCT07493447
Acoustic Neuroma, Astrocytoma
Nashville, Tennessee, United States
View Trial Details